USPSTF Recommendations For Colon Cancer Screening At Age 45 Could Give Cologuard A Boost
If the USPSTF recommendations are finalized, most insurers would need to reimburse Exact Sciences’ US FDA-approved at-home stool DNA test for colorectal cancer and encourage doctors to prescribe more at-home testing.
You may also be interested in...
JPM 2021: Intuitive Surgical, Accelerate Diagnostics, Siemens Healthineers, Exact Sciences, Renalytix
The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the third day of the meeting.
Deals give the company access to technologies to increase the accuracy of multi-cancer blood tests.
Exact Sciences Corp. and the Mayo Clinic are launching a 150,000-patient clinical trial examining the real-world effects of colorectal cancer screening with the Cologuard colon cancer test.